Efficacy and prognosis of PD-1 inhibitors, trastuzumab, and first-line chemotherapy for HER-2-positive advanced gastric cancer in real-world study

被引：0

作者：

Liu, B. ^{[1
]}

Tao, Y. ^{[1
]}

Ke, Y. ^{[1
]}

Rao, W. ^{[1
]}

Liu, Q. ^{[1
]}

机构：

[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

169P

引用

页码：S1470 / S1470

页数：1

共 50 条

[21] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
Kadowaki, Shigenori
Masuishi, Toshiki
Eto, Tetsuya
Narita, Yukiya
Taniguchi, Hiroya
Ura, Takashi
Ando, Masashi
Tajika, Masahiro
Niwa, Yasumasa
Yatabe, Yasushi
Muro, Kei
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 807 - 813
[22] A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Choong-kun Lee
Sun Young Rha
Hyo Song Kim
Minkyu Jung
Beodeul Kang
Jingmin Che
Woo Sun Kwon
Sejung Park
Woo Kyun Bae
Dong-Hoe Koo
Su-Jin Shin
Hyunki Kim
Hei-Cheul Jeung
Dae Young Zang
Sang Kil Lee
Chung Mo Nam
Hyun Cheol Chung
Nature Communications, 13
[23] A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Lee, Choong-kun
Rha, Sun Young
Kim, Hyo Song
Jung, Minkyu
Kang, Beodeul
Che, Jingmin
Kwon, Woo Sun
Park, Sejung
Bae, Woo Kyun
Koo, Dong-Hoe
Shin, Su-Jin
Kim, Hyunki
Jeung, Hei-Cheul
Zang, Dae Young
Lee, Sang Kil
Nam, Chung Mo
Chung, Hyun Cheol
NATURE COMMUNICATIONS, 2022, 13 (01)
[24] Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer
Yang, Ju
Shi, Zhan
Zhang, Xin
Liu, Qin
Cui, Xiaobin
Li, Lin
Liu, Baorui
Wei, Jia
CANCER MEDICINE, 2023, 12 (08): : 9517 - 9526
[25] Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study
Cil, Ibrahim
Kucukarda, Ahmet
Atci, Muhammed Mustafa
Secmeler, Saban
Paksoy, Nail
Ferhatoglu, Ferhat
Ak, Naziye
Ayhan, Murat
Ozyukseler, Deniz Tataroglu
Onder, Arif Hakan
Avci, Okan
Oyman, Abdilkerim
Okten, Ilker Nihat
Gulturk, Ilkay
Akagunduz, Baran
Basoglu, Tugba
Cakir, Emre
Hacibekiroglu, Ilhan
Ozcelik, Melike
Aydiner, Adnan
TUMORI JOURNAL, 2022, 108 (01): : 19 - 25
[26] Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study
Duan, Yichun
Li, Jielang
Zhou, Shuang
Bi, Feng
FRONTIERS IN IMMUNOLOGY, 2024, 15
[27] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
Wang, Q.
Xu, A.
Ma, C.
Wang, T.
Liu, P.
Duan, Y.
Kong, T.
Chen, G.
Jia, X.
Shang, K.
Yang, G.
Zhang, G.
Yu, F.
Wang, H.
Chen, H.
ANNALS OF ONCOLOGY, 2023, 34
[28] A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative
Li, Tao
Chen, Chao
Liu, Lu
Qin, Jiapei
Qiu, Lupeng
Wang, An
Dong, Weiwei
Zhang, Gehan
Li, Yao
Zhao, Lei
Zhang, Fan
Hu, Yi
CANCER MEDICINE, 2024, 13 (03):
[29] The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.
Yan, Ying
Li, Huiping
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] Immunotherapy plus chemotherapy versus chemotherapy alone in the first-line treatment for advanced gastric cancer/gastroesophageal junction cancer: a real-world retrospective study
Xu, Qian
Yi, Dan
Jia, Caiyan
Kong, Fanming
Jia, Yingjie
FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →